Naltrexone and relapse prevention treatment for cocaine-dependent patients
Abstract
A double-blind, placebo-controlled clinical trial examining the joint action of naltrexone (NTX) in combination with relapse prevention (RP) therapy for the treatment of cocaine dependence was conducted. Eighty-five participants who achieved initial abstinence during the intake evaluation and detoxification phase of the study were randomized into 1 of 4 combined NTX (0 vs. 50 mg) by therapy (RP vs. Drug Counseling) experimental conditions for the 12-week outpatient treatment phase of the study. A random effects regression model to test for group differences on percentage of cocaine-positive urines indicated a significant time by medication by therapy interaction, suggesting less cocaine use over time among subjects receiving RP-50 mg than those in the other conditions. No differences were found for retention or time until first cocaine-positive urine. Naltrexone was well tolerated by participants, with acceptable rates of medication compliance observed. Treatment integrity measures confirmed successful manipulation of the psychotherapy. These results are consistent with the notion that substance use in dependent patients can be reduced with a combination of coping skills training and pharmacologic treatments.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Relapse Prevention has been used for several types of substance abuse and has considerable empirical support.
“RP has been disseminated for treatment of several types of substance abuse (8–12) with considerable empirical support (13–20).”
From Mindfulness-Based Relapse Prevention for Substance Use Disorders: A Pilot Efficacy Trial (2009) · cites this paper as [12]
Cites
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828 · see citing works
Testing the integrity of a psychotherapy protocol: Assessment of adherence and competence
Waltz, J., Addis, M. E., Koerner, K., & Jacobson, N. S. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.4.620 · Cited by 873 · see citing works
Heroin and cocaine intravenous self-administration in rats: Mediation by separate neural systems
Ettenberg, A., Pettit, H. O., Bloom, F. E., & Koob, G. F. (1982) · Psychopharmacology · doi:10.1007/bf00428151 · Cited by 563 · see citing works
De Vry, J., Donselaar, I., & Van Ree, J. M. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20871-0 · Cited by 134 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Relapse Prevention for Alcohol and Drug Problems: That Was Zen, This Is Tao
Witkiewitz, K., & Marlatt, G. A. (2004) · American Psychologist · doi:10.1037/0003-066x.59.4.224 · Cited by 880 · see citing works
Mindfulness-Based Relapse Prevention for Substance Use Disorders: A Pilot Efficacy Trial
Bowen, S., Chawla, N., Collins, S. E., Witkiewitz, K., Hsu, S., Grow, J., Clifasefi, S., Garner, M., Douglass, A., Larimer, M. E., et al. (2009) · Substance Abuse · doi:10.1080/08897070903250084 · Cited by 715 · see citing works
Bowen, S., Witkiewitz, K., Clifasefi, S. L., Grow, J., Chawla, N., Hsu, S. H., Carroll, H. A., Harrop, E., Collins, S. E., Lustyk, M. K., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4546 · Cited by 701 · see citing works
Magill, M., & Ray, L. A. (2009) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2009.70.516 · Cited by 694 · see citing works
Mindfulness-based relapse prevention for alcohol and substance use disorders
Witkiewitz, K., Marlatt, G. A., & Walker, D. (2005) · Journal of Cognitive Psychotherapy · doi:10.1891/jcop.2005.19.3.211 · Cited by 514 · see citing works
Integrated treatment of substance use and psychiatric disorders
Kelly, T. M., & Daley, D. C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.774673 · Cited by 378 · see citing works
Ray, L. A., Meredith, L. R., Kiluk, B. D., Walthers, J., Carroll, K. M., & Magill, M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8279 · Cited by 265 · see citing works
“Rawson et al,57 2002 60 Group CBT (48) Contingency management Methadone Cocaine Percentage with negative urine screen Low −0.”
BackgroundMethodInfluentialTreatment of stimulant use disorder: A systematic review of reviews
Ronsley, C., Nolan, S., Knight, R., Hayashi, K., Klimas, J., Walley, A., Wood, E., & Fairbairn, N. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234809 · Cited by 222 · see citing works
Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020304 · Cited by 185 · see citing works
Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform
Schmitz, J. M., Mooney, M. E., Moeller, F. G., Stotts, A. L., Green, C., & Grabowski, J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.11.004 · Cited by 124 · see citing works
Self-citationEffects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial
Mooney, M. E., Herin, D. V., Schmitz, J. M., Moukaddam, N., Green, C. E., & Grabowski, J. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.016 · Cited by 124 · see citing works
Self-citationEffect of oral naltrexone on pruritus in cholestatic patients
Mansour-Ghanaei, F. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i7.1125 · Cited by 89 · see citing works
- Authors
- Schmitz, J. M., Stotts, A. L., Rhoades, H. M., & Grabowski, J.
- Affiliations
- Texas Medical Center (US)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Schmitz, Joy M
- Venue
- Addictive Behaviors
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 26
- Issue
- 2
- Pages
- 167-180
- ISSN
- 0306-4603 (ISSN-L)
- OpenAlex
- W2145470904
- Cited by
- 138
- References
- 4
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 11
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Addictive Behaviors (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50da009262-20)
- National Institute on Drug Abuse (DA09262-04)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- naltrexone, cocaine dependence, combined psychotherapy and pharmacotherapy, treatment retention, medication adherence, outpatient care, coping skills training, drug counseling
- MeSH terms
- Adaptation, Psychological, Adolescent, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Naltrexone, Narcotics, Patient Compliance, Preventive Health Services, Prospective Studies, Severity of Illness Index, Cocaine-Related Disorders, Self Efficacy, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
